CePTER Center for Personalized Translational Epilepsy Research

© Universitätklinikum Frankfurt

Epilepsies represent a pathogenetically and clinically heterogeneous group of diseases for which only relatively unspecific and symptomatically effective therapies are available. In Germany, more than 800,000 persons suffer from epilepsy. Often patients receive a correct diagnosis of their condition only after years have passed, resulting initially in incorrect treatment. And many patients do not become seizure-free or suffer from treatment-related side effects. To improve the success of epilepsy therapy, personalised and, if possible, diseasemodifying treatment (instead of merely symptomatic treatment) is required. The aim of the LOEWE research cluster CePTER is therefore the identification and validation of epilepsy-relevant disease factors, their therapeutic modification as well as the identification and validation of biomarkers of epilepsy and epileptogenesis. These goals are to be achieved with state-of-the-art molecular biological, clinical and experimental neuroscientific methods that are available to the LOEWE research network CePTER.

LOEWE Research Cluster


  • Goethe University Frankfurt am Main (lead management)
  • Fraunhofer Institute for Molecular Biology and Applied Ecology (IME)/Project Group
  • Translational Medicine and Pharmacology (IME-TMP)
  • Ernst Strüngmann Institute
  • Max Planck Institute for Empirical Aesthetics
  • Frankfurt Institute for Advanced Studies
  • Philipps-University Marburg

Fields of study

  • Medicine
  • Neurosciences
  • Computer Science
  • Life Sciences

Funding period

since 2018

Project Coordinator

  • Prof. Dr. Felix Rosenow, MHBA
    Goethe-Universität Frankfurt


  • Frankfurt am Main
  • Marburg

More Information